DREAM Study: DNA/RNA-NGS Co-Testing in Driver-Negative, Treatment-Resistant NSCLC

Key facts

Sponsor

Baohui Han

Intervention

This study did not include intervention between the two cohorts(other)

Enrollment

508 target

Eligibility

All sexes

Timeline

2025 – 2027

Study locations (1)

• Shanghai Chest Hospital, Shanghai, Shanghai Municipality, China

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for NON RARE IN EUROPE: Non-small cell lung cancer

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE1, PHASE2NCT07224152
  NBTXR3 With Radiation Therapy Alone for Locally-advanced Non-small Cell Lung Cancer
  M.D. Anderson Cancer Center
• ACTIVE NOT RECRUITINGPHASE2, PHASE3NCT05987956
  Pharmacogenomics IND EXEMPT SNP Clinical Trial - Alectinib and Single Nucleotide Polymorphisms
  Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair
• RECRUITINGPHASE2NCT07104630
  Pulmonary Rehabilitation in Advanced Lung Cancer Survivors
  Case Comprehensive Cancer Center
• RECRUITINGPHASE2NCT06878274
  Post-operative Radiotherapy After Neodjuvant Chemo-immunotherapy and Surgery in Stage III NSCLC
  Centre hospitalier de l'Université de Montréal (CHUM)
• RECRUITINGEARLY PHASE1NCT07274813
  A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX37 in Advanced/Metastatic Solid Tumors
  Shanghai Henlius Biotech
• RECRUITINGPHASE1NCT07358806
  Study to Assess the Effect of OCT-598 in Patients With Advanced Solid Tumors
  Oscotec Inc.
• RECRUITINGPHASE3NCT06686771
  Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
  Canadian Cancer Trials Group
• RECRUITINGPHASE3NCT07251582
  Effect of Infusion Timing on Pathologic Response to Neoadjuvant Immunotherapy in Resectable Non-Small Cell Lung Cancer
  Hunan Province Tumor Hospital

See all trials for NON RARE IN EUROPE: Non-small cell lung cancer →